Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.61 |
| ▸ | CMA1 | P23946 | 7/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 5/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6078614 | 1.00 | ACE (0.61) | ACECMA1F2PRSS1KLK5 | |
| SCHEMBL6920252 | 0.92 | KLK5 (0.56) | ACECMA1F2PRSS1KLK5 | |
| SCHEMBL8378100 | 0.87 | ACE (0.77) | ACECMA1F2PRSS1KLK5 | |
| SCHEMBL5900839 | 0.87 | ACE (0.77) | ACECMA1F2PRSS1KLK5 | |
| SCHEMBL22409423 | 0.87 | ACE (0.77) | ACECMA1F2PRSS1KLK5 | |
| SCHEMBL5900836 | 0.87 | ACE (0.77) | ACECMA1F2PRSS1KLK5 | |
| SCHEMBL3692081 | 0.87 | ACE (0.77) | ACECMA1F2PRSS1KLK5 | |
| SCHEMBL3692085 | 0.87 | ACE (0.77) | ACECMA1F2PRSS1KLK5 | |
| SCHEMBL24447150 | 0.86 | F2 (0.56) | ACECMA1F2PRSS1 | |
| SCHEMBL28394567 | 0.86 | F2 (0.56) | ACECMA1F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144899-B2 | Thrombin inhibitors | MERCK & CO., INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20040073025-A1 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2004-04-15 | — | — | US | disclosed |
| US-6515011-B2 | Anticoagulants | MERCK & CO., INC. | 2003-02-04 | — | — | US | disclosed |
| US-20020119992-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002064559-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002050056-A1 | BENZYLAMINE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119992-A1 | Thrombin inhibitors | SERPINC1, F2, TFPI | ACE 387/4885CMA1 365/4885F2 2/4885 |
| US-20040073025-A1 | Thrombin inhibitors | F2, F11, F10 | ACE 687/4885CMA1 141/4885F2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.